Jennifer Lippincott-Schwartz
Founder
KT
Kisbee Therapeutics
kisbeetx.com
Website unreachable since Oct 25, 2026
The startup develops a therapeutics device utilizing a proprietary technology platform to create apolipoprotein-based drugs for neurodegenerative disorders. Their focus is on providing effective treatments for conditions such as traumatic brain injury, stroke, multiple sclerosis, and Alzheimer's disease.
- Biotechnology
Updated 6 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Benjamin Cravatt
Founder
Stuart Schreiber
Founder
Product
Problem
Many neurodegenerative diseases, such as Alzheimer's, multiple sclerosis, stroke, and traumatic brain injury, are characterized by dysfunctional lipid biology in the central nervous system (CNS). Ineffective lipoprotein function and mutations in lipid transport genes disrupt lipid homeostasis, leading to excitotoxicity, impaired debris clearance, protein accumulation, inflammation, and reduced lysosomal function.
Solution
Kisbee Therapeutics is developing recombinant lipoproteins, called Kisbee Discs, engineered to target the core biological systems underlying neurodegenerative diseases. These engineered lipoproteins restore lipid homeostasis by gathering and transporting lipids to where they are needed within the CNS. By intervening in lipid dysregulation, Kisbee aims to address the underlying causes of neurodegeneration and develop effective therapies for genetically defined patient populations. The company is focused on advancing programs where biomarkers can be used to connect relevant biology to improve the ability to demonstrate efficacy.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, stroke, and traumatic brain injury, as well as the physicians and specialists who treat them.
Features
- Engineered recombinant lipoproteins (Kisbee Discs) designed to restore lipid homeostasis in the CNS
- Focus on genetically validated targets and biomarker-driven patient selection
- Programs targeting Alzheimer’s disease, rare, chronic, and acute neurodegenerative conditions
- Aims to improve lipid transport between neurons, astrocytes, and microglia
- Seeks to reduce excitotoxicity, improve debris clearance, and reduce protein accumulation and inflammation